Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 159.04
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
